BLAINTRAMUSCULARVIALPriority Review
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
27
Data completeness
6/8 — Strong
Priority Review
AVONEX (interferon beta-1a) by Biogen. Approved for interferon beta [epc]. First approved in 1996.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVONEX (interferon beta-1a) is a recombinant cytokine therapeutic administered intramuscularly as a vial formulation, approved by the FDA in May 1996 for the treatment of multiple sclerosis. The drug is manufactured by Biogen and represents one of the foundational interferon beta therapies in the MS market. While the precise mechanism of action remains incompletely understood, AVONEX is believed to modulate immune responses that drive MS pathology. It occupies a foundational but increasingly competitive position within the MS disease-modifying therapy landscape.
$0.1BPart D
Mechanism of Action
Pharmacologic Class:
Interferon beta
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (27)
Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program
Started Apr 2021
470 enrolled
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Started Oct 2019
152 enrolled
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
Started Mar 2019
11 enrolled
Multiple Sclerosis, Relapsing-Remitting
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
Started Dec 2017
168 enrolled
Relapsing Remitting Multiple Sclerosis (RRMS)
Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)
Started Nov 2017
40 enrolled
BioequivalenceHealthy
Worked on AVONEX at Biogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.